Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer

Inclusion Criteria:

- Patients aged greater than 18 years with a diagnosis of stage III non-small cell lung
cancer.

- Planned treatment with either definitive chemoradiotherapy or preoperative
chemoradiotherapy followed by surgical resection.

- PET-CT study within 4 weeks of next available DECT study.

- Patients must have measurable primary and nodal disease, defined by at least one
lesion (primary and lymph node) greater than 1 cm.

- Kidney function sufficient to tolerate iodine-based CT contrast.

- No allergy to iodine-based contrast.

- Ability to understand and the willingness to sign informed consent.

Exclusion Criteria:

- Participants with a prior history of thoracic radiotherapy.

- Participants may not be receiving any other study agents.

- Inability to tolerate CT contrast

- Pregnant women are excluded from this study because radiotherapy has the potential
for teratogenic or abortifacient effects. Because there is an unknown but potential
risk of adverse events in nursing infants secondary to treatment of the mother with
radiotherapy, breastfeeding should be discontinued if the mother is treated with
radiotherapy. These potential risks may also apply to other agents used in this
study.